Cutter Capital Management LP Takes $2.46 Million Position in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

Cutter Capital Management LP bought a new position in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA - Free Report) in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm bought 147,076 shares of the company's stock, valued at approximately $2,464,000. Centessa Pharmaceuticals comprises approximately 1.0% of Cutter Capital Management LP's investment portfolio, making the stock its 20th largest holding. Cutter Capital Management LP owned approximately 0.11% of Centessa Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Geode Capital Management LLC lifted its holdings in shares of Centessa Pharmaceuticals by 68.7% in the 3rd quarter. Geode Capital Management LLC now owns 56,597 shares of the company's stock valued at $905,000 after buying an additional 23,058 shares during the period. Franklin Resources Inc. grew its stake in shares of Centessa Pharmaceuticals by 99.1% during the 3rd quarter. Franklin Resources Inc. now owns 2,302,546 shares of the company's stock worth $38,360,000 after purchasing an additional 1,145,823 shares during the period. JPMorgan Chase & Co. grew its stake in shares of Centessa Pharmaceuticals by 1,969.2% during the 3rd quarter. JPMorgan Chase & Co. now owns 135,903 shares of the company's stock worth $2,173,000 after purchasing an additional 129,335 shares during the period. GAMMA Investing LLC increased its holdings in shares of Centessa Pharmaceuticals by 29.1% during the 4th quarter. GAMMA Investing LLC now owns 3,837 shares of the company's stock valued at $64,000 after purchasing an additional 865 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. lifted its stake in shares of Centessa Pharmaceuticals by 39.1% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 18,909 shares of the company's stock valued at $317,000 after purchasing an additional 5,316 shares during the period. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Morgan Stanley reiterated an "overweight" rating and issued a $27.00 price objective on shares of Centessa Pharmaceuticals in a research report on Friday, March 7th. TD Cowen assumed coverage on Centessa Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating on the stock. Guggenheim reaffirmed a "buy" rating and set a $28.00 target price on shares of Centessa Pharmaceuticals in a research note on Wednesday, March 26th. Finally, Piper Sandler assumed coverage on shares of Centessa Pharmaceuticals in a research note on Monday, March 31st. They issued an "overweight" rating and a $38.00 price target on the stock. Eight equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company presently has a consensus rating of "Buy" and a consensus target price of $27.71.

Insider Buying and Selling at Centessa Pharmaceuticals

In other Centessa Pharmaceuticals news, insider Karen M. Anderson sold 30,526 shares of the business's stock in a transaction dated Friday, February 7th. The shares were sold at an average price of $19.03, for a total value of $580,909.78. Following the transaction, the insider now directly owns 54,322 shares in the company, valued at $1,033,747.66. The trade was a 35.98 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, General Counsel Iqbal J. Hussain sold 6,000 shares of the firm's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $16.18, for a total transaction of $97,080.00. Following the sale, the general counsel now owns 105,386 shares of the company's stock, valued at $1,705,145.48. This represents a 5.39 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 202,353 shares of company stock worth $3,286,478 in the last three months. 11.59% of the stock is owned by corporate insiders.

Centessa Pharmaceuticals Price Performance

Shares of NASDAQ CNTA opened at $13.57 on Tuesday. The stock has a market capitalization of $1.81 billion, a price-to-earnings ratio of -8.87 and a beta of 1.53. Centessa Pharmaceuticals plc has a 52 week low of $7.75 and a 52 week high of $19.09. The firm has a 50-day simple moving average of $14.13 and a 200-day simple moving average of $15.77. The company has a quick ratio of 21.52, a current ratio of 21.52 and a debt-to-equity ratio of 0.15.

Centessa Pharmaceuticals (NASDAQ:CNTA - Get Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.34) earnings per share for the quarter, topping analysts' consensus estimates of ($0.38) by $0.04. On average, equities analysts predict that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.